摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[Cyclohexyl(piperidin-2-yl)methyl] acetate

中文名称
——
中文别名
——
英文名称
[Cyclohexyl(piperidin-2-yl)methyl] acetate
英文别名
[cyclohexyl(piperidin-2-yl)methyl] acetate
[Cyclohexyl(piperidin-2-yl)methyl] acetate化学式
CAS
——
化学式
C14H25NO2
mdl
——
分子量
239.35
InChiKey
LEMUONJQMPMKHO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.93
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:EP3305789A1
    公开(公告)日:2018-04-11
    The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.
    本发明提供了一种具有抗病毒活性的新型化合物,特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示: 其中A3为CR3A、CR3A R3B、N或NR3C;R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、基、取代或未取代的烷基、取代或未取代的炔基,或取代或未取代的非芳香碳环烷基;R3C为氢原子、取代或未取代的烷基,或取代或未取代的非芳香碳环烷基;环T1为取代或未取代的含氮非芳香杂环;R1为氢原子、卤素、基,或取代或未取代的烷基;R2分别为取代或未取代的烷基或类似物;n为1或2;R3为取代或未取代的芳香碳环烷基或类似物;R4为氢原子或羧基保护基。
  • [EN] DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS DE DIHYDROOXAZINE OU D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE BACE1
    申请人:SHIONOGI & CO
    公开号:WO2014065434A1
    公开(公告)日:2014-05-01
    The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid beta proteins. A compound of the formula (I):wherein X is -C(R3a)(R3b)-, -C(R3a)(R3b)-C(R3c)(R3d)- or -C(R3a)=C(R3c)-, R1 is substituted or unsubstituted alkyl or the like,R2a, R2b, R3a, R3b, R3c and R3d are each independently hydrogen, halogen or the like, R4 is hydrogen or halogen,Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.
    本发明提供了一种化合物,具有抑制淀粉样蛋白β产生的作用,特别是抑制BACE1的作用,并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药剂。式(I)的化合物:其中X为-C(R3a)(R3b)-,-C(R3a)(R3b)-C(R3c)(R3d)-或-C(R3a)=C(R3c)-,R1为取代或未取代的烷基或类似物,R2a、R2b、R3a、R3b、R3c和R3d分别独立地为氢、卤素或类似物,R4为氢或卤素,环B为取代或未取代的碳环或取代或未取代的杂环,或其药学上可接受的盐。
  • AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY
    申请人:Shionogi & Co., Ltd.
    公开号:US20150038483A1
    公开(公告)日:2015-02-05
    The present invention is related to a compound represented by formula (I) wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is —N(R 3 )—, —O—, or —S—; Y is ═C(R 4 )—, or ═N—; Z is —N(R 7 )—, —O—, or —S—; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: —(CR 2a R 2b ) n —R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.
    本发明涉及一种由式(I)表示的化合物,其中R1是氢原子,取代或未取代的烷基,取代或未取代的芳香环烷基等;X是—N(R3)—,—O—或—S—;Y是═C(R4)—或═N—;Z是—N(R7)—,—O—或—S—;R2是取代或未取代的烷氧基等,或以下式表示的基团:—(CR2aR2b)n—R2c,其中R2a分别是氢原子,卤素等;R2b分别是氢原子,卤素等;附在同一碳原子上的R2a和R2b可以共同形成氧化物,取代或未取代的非芳香环烷基等;附在相邻碳原子上的两个R2a和/或附在相邻碳原子上的两个R2b可以共同形成键;R2c是取代或未取代的芳香环烷基等;n是1到3的整数;R3和R7分别是氢原子,取代或未取代的烷基等;R4和R5分别是氢原子,卤素,取代或未取代的烷基等;R6是氢原子,卤素,取代或未取代的烷基等,或其药学上可接受的盐,或包含其的药物组合物。
  • [EN] A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN<br/>[FR] MÉDICAMENT DESTINÉ AU TRAITEMENT D'UNE INFECTION MYCOBACTÉRIENNE, CARACTÉRISÉ PAR LA COMBINAISON D'UN INHIBITEUR DE CYTOCHROME BC1 AVEC DE LA CLARITHROMYCINE OU DE L'AZITHROMYCINE
    申请人:SHIONOGI & CO
    公开号:WO2022119899A1
    公开(公告)日:2022-06-09
    A medicament characterized in that (A) a compound represented by formula (I):, or its pharmaceutically acceptable salt, wherein R1, R2, R3and R4are each independently hydrogen atom, halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; R5is a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like; R6, R7, R8and R9are each independently hydrogen atom, halogen or the like; X is CH or N; Y is CH or N; R10is each independently halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; m is 0, 1, 2, 3 or 4; R11is halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; R12is each independently halogen, hydroxy, cyano or the like; n is 0, 1, 2, 3 or 4; is combined with (B) clarithromycin or its pharmaceutically acceptable salt, or azithromycin or its pharmaceutically acceptable salt; and (C) clofazimine, or its pharmaceutically acceptable salt.
    一种药物,其特点在于(A)化合物由式(I)表示,或其药学上可接受的盐,其中R1、R2、R3和R4分别独立地为氢原子,卤素,羟基,基,取代或未取代的烷基或类似物;R5为氢原子,卤素,基,取代或未取代的烷基或类似物;R6、R7、R8和R9分别独立地为氢原子,卤素或类似物;X为CH或N;Y为CH或N;R10分别独立地为卤素,羟基,基,取代或未取代的烷基或类似物;m为0,1,2,3或4;R11为卤素,羟基,基,取代或未取代的烷基或类似物;R12分别独立地为卤素,羟基,基或类似物;n为0,1,2,3或4;与(B)克拉霉素或其药学上可接受的盐,或阿奇霉素或其药学上可接受的盐结合;以及(C)克罗法齐明或其药学上可接受的盐。
  • TRICYCLIC HETEROCYCLIC DERIVATIVE HAVING HIV REPLICATION-INHIBITING EFFECT
    申请人:Shionogi & Co., Ltd.
    公开号:EP3144311A1
    公开(公告)日:2017-03-22
    The present invention provides the following compound having anti-HIV activity of formula: wherein, A1 is C, CR1A or N; A2 is C, CR2A, or N; A3 is CR3A, CR3AR3B, N, NR3c O, S, SO, or SO2 ; A4 is CR4A, CR4AR4B, N, NR4C O, S, SO, or SO2; A5 is C, CR5A, or N; T1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R1 is halogen, cyano, nitro or -X1-R11; R2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R3 is hydrogen, substituted or unsubstituted aromatic varbocyclyl; R4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.
    本发明提供了以下具有抗艾滋病毒活性的式化合物: 其中,A1 是 C、CR1A 或 N; A2是C、CR2A或N A3 是 CR3A、CR3AR3B、N、NR3c O、S、SO 或 SO2 ; A4 是 CR4A、CR4AR4B、N、NR4C O、S、SO 或 SO2; A5 是 C、CR5A 或 N; T1 环是取代或未取代的单环碳环或取代或未取代的单环杂环; R1 是卤素、基、硝基或-X1-R11; R2 是取代或未取代的烷基等; n 是 1 或 2; R3 是氢、取代或未取代的芳香变环; R4 是氢或羧基保护基团; 其他符号如说明中所述。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺